NORGESTIMATE AND ETHINYL ESTRADIOL
ETHINYL ESTRADIOL; NORGESTIMATE
Approval overview NORGESTIMATE AND ETHINYL ESTRADIOL is listed in Drugs@FDA under application 205588 (ANDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient ETHINYL ESTRADIOL; NORGESTIMATE Form and strength TABLET;ORAL-28 - 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG Sponsor LUPIN LTD Submission history Latest submission status date: 2023-08-23 00:00:00.
Structured Monograph
Clinical summary
Approval overview NORGESTIMATE AND ETHINYL ESTRADIOL is listed in Drugs@FDA under application 205588 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient ETHINYL ESTRADIOL; NORGESTIMATE Form and strength TABLET;ORAL-28 - 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG Sponsor LUPIN LTD Submission history Latest submission status date: 2023-08-23 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.